PE-22-28 is an experimental peptide composed of seven amino acid residues, studied for its effect on the TREK-1 potassium channel, a protein involved in regulating the electrical activity of cells. The published evidence primarily concerns preclinical studies. The activity observed in the laboratory and the results of behavioral tests in mice make PE-22-28 an interesting subject for research. However, they do not confirm effective treatment of depression, memory disorders, or other diseases in humans. 1
The correct interpretation of literature requires distinguishing between three related but unrelated substances: the seven-amino acid fragment PE-22-28, the longer precursor peptide – sprynin – and modified analogues developed based on these structures.
These compounds are related to each other, but the results of their studies should not be combined in a way that all experiments refer to the same molecule.
What is PE-22-28? Names, synonyms and identity
The various names encountered in scientific documentation can give the impression that the available evidence base is much larger than it actually is.
The publication using the term „mini-spadin” may refer to the original fragment, its version with an amino acid sequence, or the preparation whose exact chemical form requires verification in the methodological section.
Searching by name is therefore only the first step in the identification process.
PE-22-28, PE 22-28 and PE(22-28) are variants of the entry referring to the seven-amino acid fragment associated with the studies on the propeptide derived from sortilin.
The term „mini-spadin” also appears in the literature.
The numerical range refers to the position in the precursor sequence. It does not mean that PE-22-28 contains 22 or 28 amino acids. 2
The longer peptide of the peptide is described as PE 12-28 and contains 17 amino acid residues.
Therefore, the designation PE-22-28 as „rest 22–28 of the descent” can be misleading, because the descent itself is shorter than would be suggested by such a numbering method.
The numbering in the precursor sequence must be distinguished from the length of the shortened fragment. 1
The exact identity is of particular importance when assessing later publications.
The term „analog of a scaffold” can mean the attachment of an amino acid, modification of the end of the molecule, or a coniguate.
Before assigning results to PE-22-28, the sequence and chemical characteristics in the testing methods must be verified.
Searching for literature also requires selecting the results.
A broad search for the word „spadin” in PubMed also returns publications in which it appears as the author’s surname, including articles on unrelated topics.
The number of search results is therefore not equivalent to the number of relevant experiments involving the peptide.
How is PE-22-28 classified? Peptide, protein, mixture, or other substance?
The chemical term „heptapeptide” is precise, but it answers a narrower question than the therapeutic classification.
It indicates the length of the chain, not the ability to cross biological barriers, stability in circulation, or the ability to elicit a predictable response in patients.
These properties require separate studies.
Chemically speaking, PE-22-28 is a heptapeptide, which is a compound containing seven amino acid residues linked by peptide bonds.
It is not a mixture of proteins, a steroid, or a conventional monoamine reuptake inhibitor.
Its proposed pharmacological significance is related to the modulation of the potassium channel, rather than to belonging to typical classes of antidepressants. 3
The distinction between chemical and therapeutic classification is fundamental.
The substance may be an exactly defined peptide, but at the same time it lacks evidence of efficacy, pharmacokinetics and safety in humans.
Just determining the sequence does not make it a recognized drug.
Similarly, sequential kinship with the endogenous precursor does not prove that the product produced separately behaves in the same way as the naturally occurring physiological signal.
Concentration, location, processing, exposure and formulation all influence the biological interpretation.
The test sample may also contain adjuvants, residual moisture or other components of the formulation.
They do not change the basic peptide sequence, but they affect the material specification and the significance of the declared mass or concentration.
Identity, purity, and the content of the peptide remain separate analytical issues.
The structure and composition of PE-22-28 – what has been confirmed?
In peptide studies, even a slight structural change can affect the behavior of the compound in a biological test.
Replacing the first amino acid residue or adding a chemical marker can alter the interaction with the receptor or channel, the degradation or the distribution of the substance in the tissues.
Therefore, the sequence identity must be analyzed in conjunction with the chemistry of the terminal groups and modifications.
Amino acid sequence PE-22-28
The documented sequence of amino acids is:
Gly–Val–Ser–Trp–Gly–Leu–Arg (GVSWGLR).
This sequence defines an unmodified peptide composed of seven residues.
For the unmodified compound in the chemical database, a summary formula C₃₅H₅₅N₁₁O₉ was given.
The free peptide should be distinguished from a preparation containing acetate or a chemically modified derivative, because their composition descriptions may differ. 3
Analogies and modifications of the mini-parachute
The published studies and related patent materials cover several related molecules.
Among them is an analog in which the first glycine is replaced with alanine, and derivatives containing additional chemical groups.
These are intentional structural changes, not alternative names for identical substances. 2
For reliable laboratory comparison, the documentation should specify the sequence, terminal groups, stereochemistry, information about the anti-ions, and the analytical methods used.
The claim of identity based solely on the name „mini-spadin” leaves potentially important details unresolved.
The same caution applies to the declaration of purity.
The percentage of the surface area of the chromatographic spots alone does not determine the amount of intact peptide; it does not rule out all possible impurities and does not confirm the sample's compliance with the reference material used in the experiment.
Several complementary measurements may be needed to obtain the appropriate characterization of the substance.
Scientific studies on PE-22-28 – evidence in humans, animals and in the laboratory
The available evidence can be divided into direct experiments with PE-22-28, studies of chemically modified mini-spadina analogs, and previous work on the longer precursor peptide, namely spadina.
Each category provides context, but the results should be attributed to the substance being studied.
The distinction is particularly important when the reported effect appears exceptionally long-lasting or when publications use different models of damage and behavioral tests.
Basic experiments with PE-22-28
The first studies showed a biologically plausible relationship between the truncated peptide fragment and the activity of the TREK-1 channel.
Their value stems from the combination of electrophysiology, cellular observations, and animal behavior studies, rather than from a single measurement.
Even taken together, these results do not allow for a clinical indication without direct human studies.
In the original publication from 2017, truncated analogues of spiny neurons were analyzed using electrophysiology of channels, neuron culture, and mouse models.
PE-22-28 inhibited TREK-1 activity in the studied system and was associated with behavioral results characterized as similar to antidepressant activity.
Markers related to neurogenesis and synaptogenesis were also evaluated.
These results support the preclinical hypothesis, but do not constitute observations of symptom resolution in patients. 1
The experimental sequence is important: first it shows biological activity, and then it examines whether the changes correspond to it at the level of the entire organism.
However, each subsequent stage introduces uncertainty.
The modified cellular structure does not replicate the human brain, and the behavioral screening test is not a psychiatric diagnosis.
Later studies of mini-spadynes
Later work expanded the scope of the questions from behavioral tests to neuron damage and cell survival.
This extension is scientifically relevant, but it increases the need for cautious comparisons.
Modifications in the model, the peptide preparation, the exposure, and the endpoint can both influence the direction and the magnitude of the observed response.
A 2019 study in mice analyzed a mini-stroke in models of focal cerebral ischemia and the behavior after a stroke.
Dependent on concentration, a two-phase effect was observed on TREK-1: activation at lower concentrations and inhibition at higher concentrations.
Experimental indicators of regeneration and plasticity were also observed.
The relationship between the identity of the substance under study and PE-22-28 should be verified in the publication methodology, rather than being inferred solely from the term „spadin”. 4
These results show that the description of „the TREK-1 blocker under all conditions” is too simplistic.
They also do not confirm the effectiveness of treatment for stroke.
The time of experimental intervention, the damage caused, the species, and the measurements of the results differ significantly from the conditions of clinical care for humans.
A 2021 cellular study also evaluated peptides derived from sortilin, including material known as mini-spadynin, in the context of pancreatic beta cell viability and cellular signaling.
These are laboratory-related evidence, not a clinical study regarding diabetes.
Before the results are considered a direct replication of the experiments with unmodified PE-22-28, the identity of the material used must be verified. 5
Studies of stem cell as a precursor peptide
The longer stem peptide serves as a mechanistic reference point, but does not replace the direct study of the shorter fragment.
Sequential kinship may justify the hypothesis of a common binding or signaling mechanism.
However, it does not confirm identical activity, stability, or biological distribution.
The 2010 paper on the knockdown provided important insights by linking the longer precursor peptide with TREK-1 activity and behavioral changes in mice.
A 2015 study analyzed the signaling associated with strychnine and synaptic markers in the neurons and tissues of mice.
These are important mechanistic references, but they do not confirm that all results also apply to the fragment containing seven amino acid residues. 6 7
Subsequent electrophysiological studies further clarified the pharmacological nature of the stem peptide channel.
The effects depended on the activation conditions used in the test.
This result shows the importance of the experimental context, but it still applies to the drop test, and not to the direct replication of all the results of PE-22-28. 8
Has PE-22-28 been studied in humans?
An overview of the clinical evidence should distinguish the absence of an identified registered intervention study from the evidence that no research activity exists anywhere.
The more important conclusion is that the cited documentation does not provide controlled clinical results in humans, exposure data, or a reliable safety assessment for PE-22-28.
In this review, an intervention study in humans demonstrating clinical benefit for PE-22-28 was not identified.
A targeted search in ClinicalTrials.gov for the names PE-22-28, mini-spadin, and spadin did not yield any matching studies at the time of the review. 9
This is a result of a search with a specific scope, and not proof that unrecorded or otherwise named studies cannot exist.
Studies measuring endogenous substances related to sorbitol in humans should not be equated with the administration of PE-22-28.
Biomarker dependence, animal experimentation, and clinical therapeutic research are different types of evidence.
The mechanisms of action of PE-22-28 studied scientifically
TREK-1 belongs to the potassium channel family of two-domain pores, whose members help to shape the electrical properties of cell membranes.
Researchers are analyzing whether the change in the activity of these channels affects neuronal signaling and responses to stress.
However, the interaction detected in the controlled system does not allow one to independently predict what occurs in the complex network of cells and circuits of the living human brain.
TREK-1 potassium channel
TREK-1 is a member of the potassium channel family with two pore domains.
Changes in its activity can affect the electrical properties of the cell membrane.
Scientists are investigating whether modifying this signaling is involved in neuronal and behavioral changes.
However, they do not assume that the mere existence of a channel goal allows the prediction of the therapeutic response. 8
In the original research program PE-22-28, channel activity was linked to behavioral and cellular observations.
The reported braking force is the result of a specific test.
It is not a dose for humans, a measure of clinical advantage, or a direct estimate of exposure in the brain. 1
Intracellular signaling and synaptic markers
The literature on longer synaptic transmission also discusses intracellular signaling and synaptic proteins.
The results help formulate questions about the truncated peptide, but the causal relationships require direct verification.
It is not possible to automatically transfer mechanisms based on analogies.
The common molecular target does not guarantee identical effects in subsequent signaling stages. 7
Several distinctions prevent excessive interpretations.
Increased expression of synaptic protein does not indicate an improvement in memory.
The proliferation marker does not confirm that new neurons are integrated into functional circuits.
Reduced mouse activity during the test does not mean that depression has disappeared in humans.
Any such claim requires a finite point that actually measures the given property.
Why PE-22-28 action may depend on concentration?
The two-phase results from 2019 introduce another limitation.
The direction of action on the channel may depend on the concentration and experimental conditions.
Therefore, the description of the mechanism should indicate what was observed in a specific system, rather than presenting channel inhibition as a universal property for every exposure. 4
Limitations of the scientific evidence regarding PE-22-28
The interpretation of the PE-22-28 study requires taking into account both the quality of the individual experiments and the boundaries between different types of evidence.
The molecular identity can be relatively well described, while questions regarding distribution in the human body, adverse events and clinical benefits remain almost completely open.
These are separate areas of uncertainty, not contradictions.
No confirmed clinical benefits in humans
The most important evidence gap is the difference between mechanistic and animal observations and the demonstrated therapeutic results in humans.
The identified studies do not establish the pharmacokinetic profile of PE-22-28 in humans, the clinically effective dosing regimen, the interaction profile, or long-term safety.
Has the 23-hour working time of PE-22-28 been confirmed?
The often repeated information about the 23-hour operating time requires special caution.
The detailed experiments regarding the duration of the effect from 2017 concerned modified analogs of G/A and biotinylated analogs of G/A.
They do not confirm the 23-hour half-life of unchanged PE-22-28 in humans. 1
Mixing the results of different peptides and analogues
The second limitation is the ambiguity of the identity of the substance under study.
In various studies, results regarding spadine, mini-spadine, analogs with amino acid bases, and other interventions related to TREK-1 are often combined.
A thorough review should use a compilation of evidence identifying the exact substance, model, endpoint, and comparator group before formulating a conclusion.
Limitations of animal models
The third limitation concerns the range of information that can be obtained from the experiment.
Small, controlled animal studies are useful for testing mechanisms, but the magnitude of the observed effects cannot be directly translated into the expected improvement in humans.
Independent replication of results in different laboratories, transparent reporting, and clinically relevant endpoints would increase the reliability of the evidence.
Incomplete assessment of safety
The absence of reported adverse effects does not equate to a complete safety assessment.
Studies focused on cellular behavior or parameters may not include rare adverse events, reproductive toxicity, long-term exposure, or interactions.
Missing information should remain clearly indicated, rather than being turned into claims of safety.
Frequently asked questions about PE-22-28 (Mini-Spadin)
1. Does PE-22-28 mean a specific substance?
Yes. The name of an unmodified peptide may refer to a specific sequence of seven amino acid residues GVSWGLR. Related analogs and preparations containing salts require additional characterization. Therefore, the mere similarity of the name does not confirm that the two samples have identical chemical structure or composition. 3 For the comparison to be reliable, the exact sequence, the final groups, and information about the accompanying counterions must be provided.
2. What do the available studies on PE-22-28 confirm?
They confirm preclinical activity in selected laboratory systems and animal models. The results justify further studies, but do not demonstrate clinical efficacy in humans. The claims should remain related to the investigated molecule, model, and endpoint, rather than being extended to confirmed therapeutic benefits. 1 The available results do not establish the magnitude, repeatability, or durability of the potential effect in the clinical population of humans.
3. Is PE-22-28 the same as spadyna?
No. PE-22-28 is shorter than the parent peptide containing 17 amino acid residues. Their sequential similarity helps to understand the history of the research, but does not confirm identical pharmacology or exposure. Therefore, evidence regarding one substance should be appropriately labeled before using it to discuss the other. 2 The parent peptide provides the historical context, but differences in chain length can affect stability and pharmacological activity.
4. Does the name PE-22-28 mean that the peptide contains 28 amino acids?
No. The numbers specify the range of seven positions in the precursor sequence, not the length of the fragment. Checking the actual sequence clarifies this issue and prevents confusion between the position in the precursor and the size of the isolated peptide. 3 The numbering indicates the location of the fragment within the larger molecule and should not replace a description based on the amino acid sequence.
5. Are the modified analogs interchangeable with PE-22-28?
No. Amino acid substitutions and modifications of the terminal groups form separate molecular entities. Their effects may differ, even if the majority of residues remain the same. A study of a labeled or modified analog should not be automatically cited as a study of an unmodified fragment. 2 Before comparing the results of different publications, it is necessary to specify the exact derivative used in the experiment.
6. Does stronger inhibition of TREK-1 mean better antidepressant effects?
No. The efficacy in a laboratory test does not confirm clinical benefit. The tested substance must also reach the appropriate tissues, maintain appropriate exposure, not cause unacceptable effects, and improve clinically relevant outcomes. Therefore, strong activity in one test remains an early research result and not the basis for a clinical ranking. The efficacy depends also on the conditions of the test and in itself does not say much about tissue exposure or adverse events.
7. Does the swimming test in mice allow for the recognition of depression?
No. The test measures behavior under specific experimental conditions. Such methods can be useful in preclinical studies, but they do not replicate the full disorder that occurs in humans. Interpreting them as direct evidence of depression remission or a guaranteed rapid response goes beyond the scope of measurement. Animal behavioral tests should be treated as experimental indicators rather than simplified counterparts of psychiatric diagnoses.
8. Do neurogenesis markers indicate an improvement in memory?
No. Cell markers do not directly measure memory performance. Demonstrating cognitive benefits requires appropriate behavioral or clinical tests and evidence linking the results to the proposed mechanism. A laboratory marker may support a hypothesis without confirming its practical consequences. Synaptic and cellular changes may be of mechanistic interest even if their relationship with significant cognitive outcomes remains unexplored.
9. Does the longer effect in animals confirm the half-life in humans?
No. The duration of the behavioral effect differs from the pharmacokinetic half-life. Defining exposure in humans requires validated measurements performed during the appropriate study design. Neither observation in mice nor the persistence of the effect in the test provide the missing data. The duration of pharmacodynamic activity and the elimination half-life are separate parameters that should not be used interchangeably.
10. Is the braking of the TREK-1 always the expected effect?
No. The direction and magnitude of the activity may depend on experimental conditions. Later studies of mini-spadynes have shown a biphasic behavior, therefore an unconditional description would be inappropriate. Mechanistic claims must specify the molecule and the test conditions, rather than assuming an identical response at every concentration. 4 This variability is one of the reasons why a single description of the mechanism may overlook important experimental differences.
11. Do stroke studies confirm the effectiveness of treatment for humans?
No. The model of induced brain injury in mice cannot confirm clinical efficacy in stroke. Recovery in humans depends on different causes, the time of intervention, co-morbidities, and care. Preclinical results justify the study of specific questions, but not replacing established clinical practice. The proposed involvement in post-injury plasticity does not demonstrate improvement in recovery or safety in patients.
12. Do the publications establish the dosage of PE-22-28 for humans?
No. The identified evidence does not establish a validated human use scheme. The amounts tested in animals and the concentrations used in cell tests correspond to different questions than those of the human dose selection studies. Transforming them into a self-administration protocol would overlook the missing data on exposure, safety, and clinical efficacy. Establishing doses for humans would require a separate pharmacokinetic and safety program before assessing efficacy.
13. Does PE-22-28 have proven effects that improve cognitive functions?
Not based on the evidence analyzed in this article. The result regarding signaling or synaptic marker does not confirm improvement in attention, learning, or daily functioning in humans. Such claims require direct clinical studies with appropriate control groups and validated measures of cognitive function. Appropriate endpoints should distinguish memory, attention, mood, and overall activity, rather than treating them as a single outcome.
14. Does consanguinity with the natural precursor confirm safety?
No. Sequential similarity or homology does not confirm safety when exposure is induced by administration of the substance from the outside. The distribution, persistence, impurities, and biological context still matter. The safety assessment must concern the actual preparation and intended conditions, and not be based on the claim of natural origin. A molecule related to an endogenous peptide may still exhibit different exposure, degradation, and toxicity properties.
15. Does the cleanliness report confirm the suitability of PE-22-28 for use in humans?
No. The purity measurement answers a limited analytical question. It does not replace toxicology, clinical evidence, manufacturing controls, or formulation evaluation. Even a properly identified and highly purified test sample may not possess the evidence necessary to be administered to humans. Chemical purity, identity, biological activity, and clinical utility are separate issues.
16. Does the lack of results in the clinical trial registry prove that no studies exist?
No. It only describes the result of a specific search at a specific time. Alternative names, indexing delays, and unrecorded studies may affect the availability of results. The correct conclusion is that a suitable registered study has not been identified, while taking into account the published pre-clinical literature. 9 The scope and date of the search should accompany any claim of a lack of registered studies.
17. Which studies would most increase the credibility of the evidence regarding PE-22-28?
Independent replication of the results and a clearly defined development program would be of the utmost importance. The necessary evidence includes verifiable material, reproducible pharmacological results, exposure studies, toxicology, and ethically conducted human studies. Until these questions are resolved, clinical claims remain much more uncertain than the molecular identity itself. The strongest future evidence would combine verifiable material with reproducible pharmacology, followed by carefully measured results in humans.
Conclusions
PE-22-28 is a chemically identifiable heptapeptide whose scientific documentation remains primarily preclinical.
The literature supports the study of its activity related to potassium channels, but the identity of the tested analog and the limitations of each model should be clearly indicated.
The current results do not confirm therapeutic benefits in humans nor the protocol for use in humans.
Educational, medical and research reservations
The article is purely educational in nature and serves to discuss the chemical identity and published scientific studies of PE-22-28. It does not constitute medical advice, diagnosis, therapeutic recommendation, or instructions for the purchase, preparation, administration, or combination of PE-22-28 and related substances. PE-22-28 is an experimental peptide. The laboratory and animal results cited do not confirm efficacy in the treatment of depression, stroke, memory disorders, diabetes, or other diseases in humans. Changes in potassium channel activity, synaptic markers, and behavior in mice should not be presented as proven clinical benefits. The reviewed sources do not establish a therapeutic dose, pharmacokinetic profile, long-term safety, or a validated human administration protocol. The evidence regarding sphenytoin, modified mini-sphenytoin analogs, or other formulations cannot be automatically transferred to unmodified PE-22-28. The product label, peptide sequence, and analysis certificate do not confirm the equivalence of the product with the study material or its suitability for human use. Persons with neurological, psychiatric, or other conditions should use the assessment of a qualified medical professional and not substitute established treatment with experimental substances. Scientific conclusions and regulatory information may change, therefore new claims should be evaluated based on current publications from primary sources and official regulatory sources.
References
- Djillani, A., Pietri, M., Moreno, S., Heurteaux, C., Mazella, J., & Borsotto, M. (2017). Shortened spadin analogs display better TREK-1 inhibition, in vivo stability and antidepressant activity. Frontiers in Pharmacology, 8, 643. https://doi.org/10.3389/fphar.2017.00643
- Mazella, J., Borsotto, M., Heurteaux, C., Djillani, A., Moreno, S., & Pietri, M. (2018). Peptides derived from the propeptide NTSR3 and their use in the treatment of depression (International Patent Application Publication No. WO2018069641A1). https://patents.google.com/patent/WO2018069641A1/en
- National Center for Biotechnology Information. (n.d.). PubChem compound summary for CID 165437303: L-Arginine, glycyl-L-valyl-L-seryl-L-tryptophylglycyl-L-leucyl. Retrieved October 23, 2026, from https://pubchem.ncbi.nlm.nih.gov/compound/165437303
- Pietri, M., Djillani, A., Mazella, J., Borsotto, M., & Heurteaux, C. (2019). First evidence of protective effects on stroke recovery and post-stroke depression induced by sortilin-derived peptides. Neuropharmacology, 158, 107715. https://doi.org/10.1016/j.neuropharm.2019.107715
- Daziano, G., Blondeau, N., Béraud-Dufour, S., Abderrahmani, A., Rovère, C., Heurteaux, C., Mazella, J., Lebrun, P., & Coppola, T. (2021). Sortilin-derived peptides promote pancreatic beta-cell survival through CREB signaling pathway. Pharmacological Research, 167, 105539. https://doi.org/10.1016/j.phrs.2021.105539
- Mazella, J., Pétrault, O., Lucas, G., Deval, E., Béraud-Dufour, S., Gandin, C., El-Yacoubi, M., Widmann, C., Guyon, A., Chevet, E., Taouji, S., Conductier, G., Corinus, A., Coppola, T., Gobbi, G., Nahon, J. L., Heurteaux, C., & Borsotto, M. (2010). Spadin, a sortilin-derived peptide, targeting rodent TREK-1 channels: a new concept in antidepressant drug design. PLOS Biology, 8(4), e1000355. https://doi.org/10.1371/journal.pbio.1000355
- Devader, C., Khayachi, A., Veyssière, J., Moha Ou Maati, H., Roulot, M., Moreno, S., Borsotto, M., Martin, S., Heurteaux, C., & Mazella, J. (2015). In vitro and in vivo regulation of synaptogenesis by the novel antidepressant spadin. British Journal of Pharmacology, 172(10), 2604–2617. https://doi.org/10.1111/bph.13083
- Ma, R., & Lewis, A. (2020). Spadin selectively antagonizes arachidonic acid activation of TREK-1 channels. Frontiers in Pharmacology, 11, 434. https://doi.org/10.3389/fphar.2020.00434
- National Library of Medicine. (n.d.). ClinicalTrials.gov search: PE-22-28, mini-spadin, or spadin [Database search]. Retrieved October 23, 2026, from https://clinicaltrials.gov/search?term=PE-22-28%20OR%20mini-spadin%20OR%20spadin